Alpha Cognition Patents

Patent portfolio assigned to Alpha Cognition (verified via public assignee records). Public biopharma (ACOG); ZUNVEYL/ALPHA-1062 (galantamine pro-drug), FDA-approved 2024 for Alzheimer's. has_patents=true: issued US Patent 12,589,099 (Mar 2026) for ALPHA-1062 TBI plus existing patents for ALPHA-1062 and ZUNVEYL per BioSpace press release. Exact total count not stated. No competitors/customers compiled (drug company).